Integrated mRNA-LNP Technologies and Manufacturing Platforms Supporting Personalized Cancer Vaccine Development

• ARCALIS's integrated mRNA/LNP platform combines sequence optimization, high-throughput screening, analytical characterization, and GMP-compliant manufacturing in a single workflow
• HARNA™ codon optimization, self-amplifying RNA (saRNA), and organ-selective LNP formulations deliver enhanced and sustained protein expression with optimized organ-selective delivery
• Seamless connection from discovery to GMP drug substance and drug product manufacturing enables efficient scale-up and accelerates personalized cancer vaccine development.

Speakers:

Masatoshi Mutazono, Ph.D.

Team Leader

ARCALIS